RxDoctor Payments Data

Chad Kaplan, MD

Ophthalmology · Coral Springs, FLNPI 1841580214

Payments from drug & device makers

$23,954in general payments, 2019–2025

Across 200 payments — averaging $119.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerie Pharmaceuticals, Inc.$13K
  • NEW World Medical,inc.$6K
  • Sight Sciences, Inc.$1K
  • AbbVie$1K
  • Alcon$494
  • Novartis$383
  • plus $1K from 9 others

What the payments were for

  • Consulting fees$8203%
  • Speaking & faculty fees$13,74757%
  • Travel & lodging$6713%
  • Food & beverage$8,71636%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,954 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$162,522
Medicare patients
302
Services billed
1,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost138$85,238
RhopressaNetarsudil Mesylate42$22,941
VyzultaLatanoprostene Bunod39$18,064
Prednisolone Acetate246$11,656
LumiganBimatoprost23$11,146
SimbrinzaBrinzolamide/Brimonidine Tart31$8,864
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat320$5,952
CombiganBrimonidine Tartrate/Timolol11$4,693
Azelastine Hcl131$4,457
Ketorolac Tromethamine98$2,776
Dorzolamide-TimololDorzolamide/Timolol/Pf18$2,750
MoxifloxacinMoxifloxacin Hcl111$2,667
Latanoprost214$2,417
Travoprost16$2,153
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha77$957

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$13,415$108,179180 claims
Bausch & Lomb Americas Inc.Vyzulta$66$18,06439 claims
AbbVieLumigan, Combigan$1,367$15,84034 claims
AlconSimbrinza$494$8,86431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Coral Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →